Amphastar Pharma (AMPH) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Amphastar Pharmaceuticals (AMPH) PT Raised to $18 at Jefferies
March 25, 2015 7:43 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $18.00 (from $15.00) following a narrower Q4 loss.
Steinberg commented, "AMPH Q4 EPS of -$0.03 was +0.03 ahead of our est, with higher op expenses... More
Amphastar Pharmaceuticals (AMPH) PT Raised to $19 at Piper Jaffray
March 25, 2015 6:58 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight-rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $16.00) following solid execution in Q4.
Amsellem commented, "Amphastar reported a 4Q14 net loss per share of ($0.03) on revenues of $56M, compared to the Street estimates of ($0.07) and... More
